[앵커]
GC Cell, which started commercial production as a cell therapy product called ‘Immune Cell LC’, is expanding its CDMO business by utilizing know-how and facilities for more than 10 years. In particular, as Green Cross Lab Cell and Green Cross Cell merged two years ago, synergy is being maximized. Accordingly, the company is expecting a significant number of meeting results from cell therapy companies at Interpex Korea. Reporter Kim Hyo-sun reports.
[기자]
‘GC Cell’, a company that has all the original technologies for cell therapy products, is expanding its know-how through Immunecell-LC’s cell therapy business to the CDMO business to preoccupy the specialized market in earnest.
GC Cell, which participated in Bio-Interpex Korea 2023, is active in providing one-stop total services, including know-how accumulated through cell therapy products and gene therapy products, in particular, establishing a portfolio of various cell therapy products through mergers, process development services, as well as long-term storage and logistics services. We are notifying you.
[한준희/ C> Division 부문장·GC셀 CCO(Chief Commercial Officer)]
“Immuncell-LC is the cell therapy product that has been produced in the largest amount in the world and has been administered to the most patients. So, using the know-how and facilities that we have had while producing this cell therapy for more than ten years, we will start the CDMO business. We got started, and we secured all the source technologies for cell therapy, and then we got into the CDMO business in earnest by securing the technology for gene therapy… (we jumped into it).”
The company is promoting CDMO, a differentiated cell therapy product with the supply of clinical samples in the US, production of more than 60,000 batches, and experience in treating 10,000 patients.
[한준희/ C> Division 부문장·GC셀 CCO(Chief Commercial Officer)]
“We have produced the largest number of commercial batches in the world, and we have more experience than anyone else. We are making Exact, the exact product that the client wants.”
In addition, the company has acquired the US CDMO company ‘Biocentric’ for stable entry into the US gene therapy CDMO market, and is in a position to help domestic companies quickly advance into North America.
[한준희/ C> Division 부문장·GC셀 CCO(Chief Commercial Officer)]
“We acquired a CDMO company in the United States. So, we are providing the fastest fast-track solution for domestic companies to enter North America, and overseas companies come to Korea and conduct clinical trials. We provide all the necessary parts to enter the domestic market…(We can do it.)”
In addition, GC Cell, which has obtained GMP approval for advanced biopharmaceuticals, is the only one in Korea that can provide one-stop service from clinical trials, licensing, and commercialization to global advancement, and Bio Interpex Korea plans to hold various corporate meetings related to this.
This is Pax Economy TV Kim Hyo-sun.
Cinematographer: Kim Hong-mo / Editing: Park Hyeon-seong
Copyright © Pax Economy TV Unauthorized reproduction and redistribution prohibited
2023-07-13 00:39:54
#인터펙스코리아2023영상 #Cell #Cell #therapy #CDMO #business #utilizing #rich #experience…partnering #meeting #flooded
